Latest Financials News

Page 557 of 1335
Visionflex Group Limited’s FY25 results highlight a strong transition to a SaaS-driven model, with recurring revenue surging 49% to $1.9 million and total revenue up 33%. Key government and private sector contracts underpin future growth prospects.
Victor Sage
Victor Sage
29 Aug 2025
Visionflex Group reported a 49% rise in annual recurring revenue to $1.9 million despite a 33% drop in total revenue, driven by a pivot to subscription models and key government and corporate contracts.
Victor Sage
Victor Sage
29 Aug 2025
Vection Technologies reported a 9.6% revenue increase to $36 million and a 25.3% reduction in net loss for FY2025, driven by operational improvements and a key acquisition.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Virgin Australia reported a 3% revenue increase and a 28% rise in underlying EBIT for FY25, while statutory net profit fell 12% due to IPO and Qatar Airways transaction costs. The airline expanded its fleet and loyalty program amid ongoing transformation efforts.
Victor Sage
Victor Sage
29 Aug 2025
Novatti Group Limited reported a 24.1% revenue increase to $50.48 million for FY2025 alongside a 69.7% reduction in losses. However, the company’s balance sheet weakness and ongoing audit spotlight raise questions about its financial sustainability.
Claire Turing
Claire Turing
29 Aug 2025
Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.
Ada Torres
Ada Torres
29 Aug 2025
Visionflex Group Limited reported a sharp 33% decline in revenues and a 69% increase in net losses for FY25, with auditors flagging material uncertainty over the company’s ability to continue as a going concern.
Ada Torres
Ada Torres
29 Aug 2025
Bapcor Limited reported a modest revenue decline and an 8.4% drop in pro-forma NPAT for FY25 amid significant business simplification and strategic initiatives aimed at sustainable growth.
Victor Sage
Victor Sage
29 Aug 2025
PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.
Victor Sage
Victor Sage
29 Aug 2025
Mesoblast reports a strong FY2025 financial performance driven by the commercial launch of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in children. The company is advancing multiple clinical programs targeting inflammatory diseases, heart failure, and chronic low back pain.
Ada Torres
Ada Torres
29 Aug 2025
Scalare Partners reports a 26% rise in FY25 revenue, driven by strong service demand and key acquisitions, including Inhouse Ventures and the pending Tank Stream Labs deal.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Xamble Group Limited reported a sharp 39% revenue decline and a doubling of losses in H1 FY2025, driven by strategic exit from Taiwan and increased technology spending. Despite financial setbacks, operational metrics show strong user and client growth, underpinning the company’s Southeast Asia-focused transformation.
Sophie Babbage
Sophie Babbage
29 Aug 2025